Amgen (AMGN) operates within a competitive landscape of six major pharmaceutical peers, ranking second in both sales growth and operating margins while trading at a premium valuation relative to some rivals. The company's financial profile shows it outperforming Johnson & Johnson in revenue growth and profitability, yet commanding a lower P/E multiple than AbbVie despite superior growth metrics. This valuation disconnect suggests the market prices in continued growth deceleration. Amgen's performance is heavily driven by six key therapeutic areas that collectively accounted for nearly 70% of product sales in fiscal Q2 2026. While blockbuster drug Repatha saw a significant 37% sales increase, the company faces headwinds from biosimilar competition impacting Prolia and XGEVA, which combined sales fell by 33%. Overall revenue growth has slowed sequentially from previous years, with the market anticipating this trend to persist. Management raised its full-year 2026 revenue guidance to a midpoint of $38.8 billion, representing approximately 5% growth over the prior year's reported results. However, executives warned that operating expenses will rise meaningfully in the third quarter due to increased spending on pipeline development and commercial brands, posing a potential risk to the company's historically strong operating margins. The article concludes that investors should monitor Amgen's full-year 2026 revenue against its guidance range as the primary metric for assessing whether the stock's valuation assumptions regarding growth slowdown hold true. The narrative balances the success of core assets like Repatha against the erosion from biosimilars and rising cost pressures.